Literature DB >> 25356715

Evaluation of outcome and prognostic factors for dogs living greater than one year after diagnosis of osteosarcoma: 90 cases (1997-2008).

William T N Culp1, Francisco Olea-Popelka, Jennifer Sefton, Charles F Aldridge, Stephen J Withrow, Mary H Lafferty, Robert B Rebhun, Michael S Kent, Nicole Ehrhart.   

Abstract

OBJECTIVE: To evaluate clinical characteristics, outcome, and prognostic variables in a cohort of dogs surviving > 1 year after an initial diagnosis of osteosarcoma.
DESIGN: Retrospective case series. ANIMALS: 90 client-owned dogs. PROCEDURES: Medical records for an 11-year period from 1997 through 2008 were reviewed, and patients with appendicular osteosarcoma that lived > 1 year after initial histopathologic diagnosis were studied. Variables including signalment, weight, serum alkaline phosphatase activity, tumor location, surgery, and adjuvant therapies were recorded. Median survival times were calculated by means of a Kaplan-Meier survival function. Univariate analysis was conducted to compare the survival function for categorical variables, and the Cox proportional hazard model was used to evaluate the likelihood of death > 1 year after diagnosis on the basis of the selected risk factors.
RESULTS: 90 dogs met the inclusion criteria; clinical laboratory information was not available in all cases. Median age was 8.2 years (range, 2.7 to 13.3 years), and median weight was 38 kg (83.6 lb; range, 21 to 80 kg [46.2 to 176 lb]). Serum alkaline phosphatase activity was high in 29 of 60 (48%) dogs. The most common tumor location was the distal portion of the radius (54/90 [60%]). Eighty-nine of 90 (99%) dogs underwent surgery, and 78 (87%) received chemotherapy. Overall, 49 of 90 (54%) dogs developed metastatic disease. The median survival time beyond 1 year was 243 days (range, 1 to 1,899 days). Dogs that developed a surgical-site infection after limb-sparing surgery had a significantly improved prognosis > 1 year after osteosarcoma diagnosis, compared with dogs that did not develop infections. CONCLUSIONS AND CLINICAL RELEVANCE: Results of the present study indicated that dogs with an initial diagnosis of osteosarcoma that lived > 1 year had a median survival time beyond the initial year of approximately 8 months. As reported previously, the development of a surgical-site infection in dogs undergoing a limb-sparing surgery significantly affected prognosis and warrants further study.

Entities:  

Mesh:

Year:  2014        PMID: 25356715      PMCID: PMC4556346          DOI: 10.2460/javma.245.10.1141

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  29 in total

1.  Prognostic significance of a new histologic grading system for canine osteosarcoma.

Authors:  J Kirpensteijn; M Kik; G R Rutteman; E Teske
Journal:  Vet Pathol       Date:  2002-03       Impact factor: 2.221

2.  Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma.

Authors:  C K Garzotto; J Berg; W E Hoffmann; W M Rand
Journal:  J Vet Intern Med       Date:  2000 Nov-Dec       Impact factor: 3.333

3.  Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs.

Authors:  Michael S Kent; Adam Strom; Cheryl A London; Bernard Seguin
Journal:  J Vet Intern Med       Date:  2004 Jul-Aug       Impact factor: 3.333

4.  Four fraction palliative radiotherapy for osteosarcoma in 24 dogs.

Authors:  Eric M Green; William M Adams; Lisa J Forrest
Journal:  J Am Anim Hosp Assoc       Date:  2002 Sep-Oct       Impact factor: 1.023

Review 5.  Update on the biology and management of canine osteosarcoma.

Authors:  Ruthanne Chun; Louis-Philippe de Lorimier
Journal:  Vet Clin North Am Small Anim Pract       Date:  2003-05       Impact factor: 2.093

6.  Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs.

Authors:  Brenda Phillips; Barbara E Powers; William S Dernell; Rod C Straw; Chand Khanna; Gary S Hogge; David M Vail
Journal:  J Am Anim Hosp Assoc       Date:  2009 Jan-Feb       Impact factor: 1.023

7.  Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin.

Authors:  G N Mauldin; R E Matus; S J Withrow; A K Patnaik
Journal:  J Vet Intern Med       Date:  1988 Oct-Dec       Impact factor: 3.333

8.  Use of an ipsilateral vascularized ulnar transposition autograft for limb-sparing surgery of the distal radius in dogs: an anatomic and clinical study.

Authors:  Bernard Séguin; Peter J Walsh; David R Mason; Erik R Wisner; Jessica L Parmenter; William S Dernell
Journal:  Vet Surg       Date:  2003 Jan-Feb       Impact factor: 1.495

Review 9.  Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.

Authors:  Ilse Boerman; Gayathri T Selvarajah; Mirjam Nielen; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2012-05-15       Impact factor: 2.741

10.  Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.

Authors:  L E Selmic; J H Burton; D H Thamm; S J Withrow; S E Lana
Journal:  J Vet Intern Med       Date:  2014-02-10       Impact factor: 3.333

View more
  9 in total

1.  Immune dysregulation and osteosarcoma: Staphylococcus aureus downregulates TGF-β and heightens the inflammatory signature in human and canine macrophages suppressed by osteosarcoma.

Authors:  Joanne L Tuohy; Jason A Somarelli; Luke B Borst; William C Eward; B Duncan X Lascelles; Jonathan E Fogle
Journal:  Vet Comp Oncol       Date:  2019-10-15       Impact factor: 2.613

2.  Treatment of extraskeletal osteosarcoma at a previous injection site resulting in prolonged survival in 1 dog.

Authors:  Laura E Selmic; Lynn R Griffin; Megan H Rector; Mary Lafferty; Roy Pool; Nicole P Ehrhart
Journal:  Can Vet J       Date:  2016-09       Impact factor: 1.008

Review 3.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

Review 4.  The immunotherapy of canine osteosarcoma: a historical and systematic review.

Authors:  K L Wycislo; T M Fan
Journal:  J Vet Intern Med       Date:  2015-04-30       Impact factor: 3.333

Review 5.  Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics.

Authors:  Siobhan Simpson; Mark David Dunning; Simone de Brot; Llorenç Grau-Roma; Nigel Patrick Mongan; Catrin Sian Rutland
Journal:  Acta Vet Scand       Date:  2017-10-24       Impact factor: 1.695

6.  Prognostic value of fluorine18 flourodeoxyglucose positron emission tomography/computed tomography in dogs with appendicular osteosarcoma.

Authors:  Lynn R Griffin; Douglas H Thamm; Ariel Brody; Laura E Selmic
Journal:  J Vet Intern Med       Date:  2019-02-15       Impact factor: 3.333

Review 7.  The Importance of the Tumor Microenvironment and Hypoxia in Delivering a Precision Medicine Approach to Veterinary Oncology.

Authors:  Mark Gray; James Meehan; Arran K Turnbull; Carlos Martínez-Pérez; Charlene Kay; Lisa Y Pang; David J Argyle
Journal:  Front Vet Sci       Date:  2020-11-12

8.  Dog breeds and body conformations with predisposition to osteosarcoma in the UK: a case-control study.

Authors:  Sam Beck; Rachel J Errington; Sara Gould; Helen Winter; Grace L Edmunds; Matthew J Smalley; Dave C Brodbelt; Dan G O'Neill
Journal:  Canine Med Genet       Date:  2021-03-10

9.  A Target Animal Effectiveness Study on Adjuvant Peptide-Based Vaccination in Dogs with Non-Metastatic Appendicular Osteosarcoma Undergoing Amputation and Chemotherapy.

Authors:  Laura Marconato; Alessia Melacarne; Marina Aralla; Silvia Sabattini; Luca Tiraboschi; Valentina Ferrari; Offer Zeira; Andrea Balboni; Eugenio Faroni; Dina Guerra; Luciano Pisoni; Erica Ghezzi; Letizia Pettinari; Maria Rescigno
Journal:  Cancers (Basel)       Date:  2022-03-06       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.